In a HER2-transgenic breast cancer mouse model, co-administration of T-DXd with CD47 checkpoint blockade significantly enhanced antitumor immune responses and induced durable CD8+ T cell memory following treatment cessation[20]. This evidence concerns the gene ERBB2 and breast carcinoma.